Tinnitus (Ear Nose Throat Disorders) - Drugs In Development, 2021

July 2021 | 63 pages | ID: T0C7F9D7B287EN
Global Markets Direct

Abstracts

Tinnitus (Ear Nose Throat Disorders) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus - Drugs In Development, 2021, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinnitus - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).
• The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Tinnitus - Overview
Tinnitus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tinnitus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tinnitus - Companies Involved in Therapeutics Development
AudioCure Pharma GmbH
Auris Medical Holding Ltd
Autifony Therapeutics Ltd
Cognosetta Inc
Gateway Biotechnology Inc
Knopp Biosciences LLC
Otonomy Inc
Sensorion SA
Tinnitus - Drug Profiles
AC-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-0022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esketamine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gacyclidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-3061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RL-81 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate KCNQ2 and KCNQ3 for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetrandrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tinnitus - Dormant Projects
Tinnitus - Discontinued Products
Tinnitus - Product Development Milestones
Featured News & Press Releases
Jun 16, 2021: Light E.N.T. announces first patient enrolled in drug trial for treatment of tinnitus (Ringing Sound in Ear)
Apr 05, 2021: Otonomy announces presentation of OTO-313 clinical results at American Neurotology Society Annual Meeting
Mar 25, 2021: Otonomy initiates phase 2 clinical trial of OTO-313 in Tinnitus
Nov 30, 2020: Otonomy provides update on OTO-313 program
Jul 06, 2020: Otonomy reports positive top-line results from phase 1/2 clinical trial of OTO-313 in patients with tinnitus
Jun 22, 2020: CogInc receives Bull Ring Accelerator Funding
Apr 08, 2020: CogInc awarded AOHL's Flexi grant
Jan 10, 2020: Auris Medical announces notice of allowance for European Patent Application
Dec 17, 2019: Cognosetta: SBIR grant awarded
Sep 13, 2019: Auris Medical receives FDA and EMA Guidance for Keyzilen late-stage clinical development program
Aug 26, 2019: Auris Medical announces formation of scientific advisory board for tinnitus programs
May 23, 2019: Auris Medical provides update on Keyzilen
Apr 25, 2019: Auris Medical provides update on Tinnitus Drug Development Strategy
Apr 11, 2019: Otonomy initiates phase 1/2 Clinical Trial of OTO-313 in Tinnitus
Feb 06, 2019: Otonomy announces presentation on tinnitus drug OTO-313 at Association for Research in Otolaryngology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Tinnitus, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Tinnitus - Pipeline by AudioCure Pharma GmbH, 2021
Tinnitus - Pipeline by Auris Medical Holding Ltd, 2021
Tinnitus - Pipeline by Autifony Therapeutics Ltd, 2021
Tinnitus - Pipeline by Cognosetta Inc, 2021
Tinnitus - Pipeline by Gateway Biotechnology Inc, 2021
Tinnitus - Pipeline by Knopp Biosciences LLC, 2021
Tinnitus - Pipeline by Otonomy Inc, 2021
Tinnitus - Pipeline by Sensorion SA, 2021
Tinnitus - Dormant Projects, 2021
Tinnitus - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Tinnitus, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Types, 2021